Participated · Series D · Nov 2023

Supira Medical, a Shifamed portfolio company based in Los Gatos, Calif., is developing the Supira System, an investigational next-generation pVAD intended for HRPCI and cardiogenic shock. The company recently completed enrollment of its U.S. SUPPORT I Early Feasibility Study, enrolling 15 patients across four clinical sites, and reports the Supira System has benefited 85 HRPCI patients to date. The device is investigational and not approved for sale in the U.S. or elsewhere. Supira plans to expand its clinical programs for both HRPCI and cardiogenic shock, including the SUPPORT II U.S. Pivotal Study for HRPCI that will be used to seek FDA PMA approval. The company aims to use new capital to accelerate those clinical programs and further validate its low-profile, high-flow technology platform. Supira Medical is advancing the Supira System, a percutaneous ventricular assist device (pVAD) featuring a novel low-profile, high continuous-flow design intended to provide full hemodynamic support initially for high-risk percutaneous coronary interventions and subsequently for cardiogenic shock. The system is built with a 10F profile to minimize vascular complications and incorporates multiple sensors for real-time pressure measurements. The Supira System is for investigational use only and is not for sale in the U.S. or outside the U.S. Supira is led by President and CEO Dr. Nitin Salunke and is a portfolio company of Shifamed, LLC. The company plans to expand its currently enrolling OUS studies, plan for U.S. studies, and prepare for a U.S. pivotal study submission. It raised $40M in Series D financing to support those clinical and regulatory activities. Supira Medical is developing a next-generation percutaneous ventricular assist device (pVAD) intended to provide temporary mechanical circulatory support for high-risk patients. The device is aimed for use during interventional procedures such as stent placement or angioplasty and to treat patients suffering from cardiogenic shock following severe heart attacks. The company is led by CEO Dr. Nitin Salunke and is a Shifamed portfolio company based in Los Gatos, CA. Supira plans to finalize product development and initiate a first-in-human clinical study for its pVAD. Financially, the company recently completed a financing round to support those activities. Supira Medical is focused on developing a next-generation percutaneous ventricular assist device (pVAD) for use in high-risk patients undergoing interventional procedures. The company was formed as the newest portfolio company of Shifamed and is located in Shifamed's facility in Silicon Valley. Jean Orth was appointed CEO in December 2017 and brings more than 25 years of cardiology-centric medical device experience. Supira closed a $15.5M financing that officially closed on April 25, 2018 to support its early development efforts. The round was led by The Capital Partnership with participation from Cormorant Asset Management and Shifamed Angels. Shifamed's incubator track record includes multiple exits, providing an experienced sponsor and potential exit pathways for its portfolio companies.

Participated · Series B · Jun 2023

Myra Vision is developing a treatment intended to allow maximum intraocular pressure (IOP) reduction for patients with moderate to advanced glaucoma. The company is developing the Calibreye System, a novel treatment designed to allow safe outflow control to achieve maximum IOP reduction while reducing complexity and complication rates. Myra Vision is led by President and CEO Robert Chang. The company intends to use new funding to further product development, scale manufacturing capabilities, and support first-in-human investigation of the Calibreye System. It is a privately held portfolio company of Shifamed. The firm completed a $25M Series B to support these activities. Myra Vision is developing a glaucoma treatment device built around novel technology designed to allow safe outflow control to achieve maximum intraocular pressure (IOP) reduction while reducing complexity and complication rates. The company is based in Campbell, Calif., and is a Shifamed portfolio company. Led by CEO Robert Chang, Myra Vision intends to use its recent financing to advance product development, scale infrastructure, and expand its team. The company completed a $17M Series A financing and announced a name change to Myra Vision, Inc. from Myra Medical, Inc. The funding is intended to support continued development and commercialization efforts for its glaucoma treatment device. Myra Medical is a newly formed Shifamed portfolio company advancing surgical devices designed to enable maximum intraocular pressure (IOP) reduction. Its novel technology aims to safely reduce IOP while lowering the risk of hypotony, targeting improved treatment for moderate to advanced glaucoma patients. The company intends to use its recent funding to advance product development and pre-clinical programs. Myra Medical has appointed Robert Chang as Chief Executive Officer and Tracy Valorie as a strategic advisor; both bring extensive ophthalmology and medical-device experience. The company raised seed financing in 2019 to support these development plans. Shifamed, founded by serial entrepreneur Amr Salahieh, serves as the medical innovation hub backing the company.

Participated · Series B · May 2022

Adona Medical is a pre-clinical medical technology company focused on solutions for advanced heart failure. It is developing an adjustable interatrial shunt with integrated bi-atrial pressure monitoring alongside remote patient monitoring components as part of a heart failure management platform. The platform is investigational and not approved for use in the U.S. or elsewhere. The company plans to use newly raised capital to further product development and to initiate clinical use of the adjustable interatrial shunt and monitoring capabilities. Adona Medical raised $33.5M in a Series C financing to support those plans. The company is a Los Gatos, CA–based Shifamed portfolio company led by CEO Brian Fahey. Adona Medical is a pre-clinical stage medical technology company developing a next-generation heart failure management platform. The company is led by CEO Brian Fahey and is a privately held portfolio company of Shifamed LLC. Its core work focuses on next-generation solutions for patients with advanced heart failure. Adona intends to use new funding to complete product development and to support further evaluation of its platform. The article does not provide operating metrics such as revenue or user counts. Adona is based in Campbell, California. Adona Medical focuses on advanced interventional approaches for heart failure. The company is a privately held portfolio company of medical innovation hub Shifamed LLC and is based in Campbell, CA. It raised $2.5M in seed financing to advance product development and expand its intellectual property portfolio. The round was funded exclusively by select Shifamed accredited angel investors. Leadership includes newly appointed CEO Brian Fahey and Chairman Amr Salahieh. Fahey joins Adona with over 15 years of medtech leadership and product development experience.